XML 146 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other disclosures (Tables)
 12 Months Ended
Dec. 31, 2023
Additional information [abstract]  
Share-based payment expensed in the income statement
Share-based payment expensed in the income statement
DKK million202320222021
Restricted stock units to employees365265189
Long-term share-based incentive programme (Management Board)1
304250234
Long-term share-based incentive programme (Management group below Management Board)1,271819598
Restricted stock units to individual employees20920519
Share-based payment expensed in the income statement2,1491,5391,040
1. In 2021, Novo Nordisk introduced a new share-based compensation programme with terms, which amortises the grant date valuation over three years (the 2020 programme was amortised over four years). The 2023 expense includes amortisation of the 2020, 2021, 2022 and 2023 programmes.
Outstanding restricted stock units
General terms and conditions of 2020-2023 programmes1
Employees' 100 year anniversary programmeManagement BoardManagement group below Management BoardIndividual employees
202320232022202120202023202220212020202320222021
Preliminary number of shares to be allocated2 (million)
3.0 0.6 0.7 1.0 0.9 3.1 3.3 3.0 2.4 0.3 0.8 0.3 
Fair value per restricted stock unit at grant date (DKK)446 456 320 212 206 456 320 212 206 544 371 269 
Performance and vesting period2023 to 20262023 to 20252022 to 20242021 to 20232020 to 20232023 to 20252022 to 20242021 to 20232020 to 20232023 to 20262022 to 20252021 to 2024
Allocation dateAug 2026Feb 2026Feb 2025Feb 2024Feb 2024Feb 2026Feb 2025Feb 2024Feb 2024202620252024
Amortisation period3.5 years3 years3 years3 years4 years3 years3 years3 years4 years3 years3 years3 years
1. As of 13 September 2023, the trading unit of the Novo Nordisk B shares listed on NASDAQ Copenhagen and ADRs listed on the New York Stock Exchange (NYSE) was changed from DKK 0.20 to DKK 0.10. Comparative figures have been restated to reflect the change in trading unit from DKK 0.20 to DKK 0.10. 2. The number of shares to be allocated under the LTIPs to Management Board and management group below Management Board, respectively, may potentially be reduced or increased depending on whether Novo Nordisk's performance during the three-year performance period is higher or lower compared to targets determined by the Board. The maximum number is capped.
Contractual obligations not recognised in the balance sheet
Contractual obligations not recognised in the balance sheet
DKK million (undiscounted)CurrentNon-currentTotal
2023
Leases1
144 2,053 2,197
Research and development obligations8,678 13,235 21,913
Research and development – potential milestone payments2
1,234 27,311 28,545
Commercial product launch – potential milestone payments2
— 12,952 12,952
Purchase obligations relating to investments in property, plant and equipment4,222 1,693 5,915
Purchase obligations relating to contract manufacturers6,315 26,792 33,107
Other purchase obligations7,151 5,888 13,039
Total obligations not recognised in the balance sheet27,744 89,924 117,668
2022
Leases1
205 1,641 1,846 
Research and development obligations5,988 7,582 13,570 
Research and development – potential milestone payments2
376 5,011 5,387 
Commercial product launch – potential milestone payments2
— 7,598 7,598 
Purchase obligations relating to investments in property, plant and equipment1,696 1,427 3,123 
Purchase obligations relating to contract manufacturers3,537 9,825 13,362
Other purchase obligations15,225 4,541 19,766 
Total obligations not recognised in the balance sheet27,027 37,625 64,652 
1. Predominantly relates to estimated variable property taxes, leases committed but not yet commenced and low value leases. 2. Potential milestone payments are associated with uncertainty because they are linked to successful achievements in research activities.
Fair value of recognized assets and liabilities
Fair value recognised at date of acquisition
2022
DKK millionForma Therapeutics
Intellectual property rights5,766
Other intangible assets492
Financial assets77
Marketable securities1,470
Cash1,027
Deferred tax assets (liabilities), net(709)
Other net assets(21)
Net identifiable assets acquired8,102
Goodwill—
Consideration transferred8,102
Cash acquired(1,027)
Cash used for acquisition of businesses7,075
Material transactions with related parties
Material transactions with related parties
DKK million202320222021
Novo Holdings A/S
Purchase of Novo Nordisk B shares8,7756,9846,695
Dividend payment to Novo Holdings A/S9,0287,2076,144
NNIT Group
Services provided by NNIT436660593
Dividend payment from NNIT——(4)
Altasciences Group
Services provided by Novo Nordisk———
Services provided by Altasciences2297011
Novozymes Group
Services provided by Novo Nordisk(48)(78)(116)
Services provided by Novozymes1129278
Fee to statutory auditors
DKK million202320222021
Statutory audit1
303826
Audit-related services323
Tax advisory services834
Other services18124
Total fees to statutory auditors595537
1. 2022 statutory audit fee includes DKK 9 million of additional fee related to 2021.
Companies in the Novo Nordisk Group
Company and countryActivity
Parent company
Novo Nordisk A/S, Denmark••••
Subsidiaries by geographical area
Company and countryPercentage of shares ownedActivity
North America Operations
Inversago Pharma Inc., Canada100•
Novo Nordisk Canada Inc., Canada100•
Novo Nordisk North America Operations A/S, Denmark100•
Novo Nordisk Inc., US100•
Novo Nordisk Pharmaceutical Industries LP, US100•
Novo Nordisk Pharmatech US, Inc., US100•
Novo Nordisk Pharma, Inc., US100•
Novo Nordisk Research Center Indianapolis, Inc., US100•
Novo Nordisk Research Center Seattle, Inc., US100•
Novo Nordisk US Bio Production, Inc., US100•
Novo Nordisk US Commercial Holdings, Inc., US100•
Novo Nordisk US Holdings Inc., US100•
Dicerna Pharmaceuticals, Inc., US100•
Emisphere Technologies, Inc., US100•
Forma Therapeutics, Inc., US100•
Region International Operations
Novo Nordisk Pharmaceuticals A/S, Denmark100•
Novo Nordisk Pharma Operations A/S, Denmark100••
Novo Nordisk Region AAMEO and LATAM A/S, Denmark100•
Novo Nordisk Region Europe A/S, Denmark100•
Novo Nordisk Region Japan & Korea A/S, Denmark100•
Region EMEA
Aldaph SpA, Algeria100••
Novo Nordisk Pharma GmbH, Austria100•
S.A. Novo Nordisk Pharma N.V., Belgium100•
Novo Nordisk Pharma d.o.o., Bosnia and Herzegovina100•
Novo Nordisk Pharma EAD, Bulgaria100•
Novo Nordisk Hrvatska d.o.o., Croatia100•
Novo Nordisk s.r.o., Czech Republic100•
Novo Nordisk Denmark A/S, Denmark100•
Novo Nordisk Pharmatech A/S, Denmark100••
Novo Nordisk Egypt LLC, Egypt100•
Novo Nordisk Egypt Pharmaceuticals Ltd., Egypt100•
Company and countryPercentage of shares ownedActivity
Novo Nordisk Estonia OÜ, Estonia100•
Novo Nordisk Farma OY, Finland100•
Biocorp Production S.A., France100••
Novo Nordisk, France100•
Novo Nordisk Production SAS, France100•
Novo Nordisk Pharma GmbH, Germany100•
Novo Nordisk Hellas Epe., Greece100•
Novo Nordisk Hungária Kft., Hungary100•
Novo Nordisk Limited, Ireland100•
Novo Nordisk Ltd, Israel100•
Novo Nordisk S.P.A., Italy100•
Novo Nordisk Kazakhstan LLP, Kazakhstan100•
Novo Nordisk Kenya Ltd., Kenya100•
Novo Nordisk Latvia SIA, Latvia100•
Novo Nordisk Pharma SARL, Lebanon100•
UAB Novo Nordisk Pharma, Lithuania100•
Novo Nordisk Farma dooel, North Macedonia100•
Novo Nordisk Pharma SAS, Morocco100•
Novo Nordisk B.V., Netherlands100•
Novo Nordisk Finance (Netherlands) B.V., Netherlands100•
Novo Nordisk Pharma Limited, Nigeria100•
Novo Nordisk Norway AS, Norway100•
Novo Nordisk Pharmaceutical Services Sp. z.o.o., Poland100•
Novo Nordisk Pharma Sp.z.o.o., Poland100•
Novo Nordisk Portugal, Lda., Portugal100•
Novo Nordisk Farma S.R.L., Romania100•
Novo Nordisk Limited Liability Company, Russia100••
Novo Nordisk Production Support LLC, Russia100•
Novo Nordisk Saudi for Trading, Saudi Arabia100•
Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Serbia100•
Novo Nordisk Slovakia s.r.o., Slovakia100•
Novo Nordisk, d.o.o., Slovenia100•
Novo Nordisk (Pty) Limited, South Africa100•
Novo Nordisk Pharma S.A., Spain100•
Novo Nordisk Scandinavia AB, Sweden100•
Novo Nordisk Health Care AG, Switzerland100•••
Novo Nordisk Pharma AG, Switzerland100•
Novo Nordisk Tunisie SARL, Tunisia100•
Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Turkey100•
Novo Nordisk Ukraine, LLC, Ukraine100•
Novo Nordisk Pharma Gulf FZE, United Arab Emirates100•
Novo Nordisk Holding Limited, UK100•
Novo Nordisk Limited, UK100•
Novo Nordisk Research Centre Oxford Limited, UK100•

Company and countryPercentage of shares ownedActivity
Region China
Novo Nordisk (China) Pharmaceuticals Co. Ltd., China100••
Novo Nordisk (Shanghai) Pharma Trading Co., Ltd., China100•
Novo Nordisk Region China A/S, Denmark100•
Novo Nordisk Hong Kong Limited, Hong Kong100•
Novo Nordisk Pharma (Taiwan) Ltd., Taiwan100•
Beijing Novo Nordisk Pharmaceuticals Science & Technology Co., Ltd., China100•
Region Rest of World
Novo Nordisk Pharma Argentina S.A., Argentina100•
Novo Nordisk Pharmaceuticals Pty. Ltd., Australia100•
Novo Nordisk Pharma (Private) Limited, Bangladesh100•
Novo Nordisk Produção Farmacêutica do Brasil Ltda., Brazil100•
Novo Nordisk Farmacêutica do Brasil Ltda., Brazil100•
Novo Nordisk Farmacéutica Limitada, Chile100•
Novo Nordisk Colombia SAS, Colombia100•
Novo Nordisk India Private Limited, India100•
Novo Nordisk Service Centre (India) Pvt. Ltd., India100•
PT. Novo Nordisk Indonesia, Indonesia100•
Novo Nordisk Pars, Iran100••
Novo Nordisk Pharma Ltd., Japan100••
Novo Nordisk Pharma (Malaysia) Sdn Bhd, Malaysia100•
Novo Nordisk Pharma Operations Sdn Bhd, Malaysia100•
Novo Nordisk Mexico S.A. de C.V., Mexico100•
Novo Nordisk Pharmaceuticals Ltd., New Zealand100•
Novo Nordisk Pharma (Private) Limited, Pakistan100•
Novo Nordisk Panama S.A., Panama100•
Novo Nordisk Peru S.A.C., Peru100•
Novo Nordisk Pharmaceuticals (Philippines) Inc., Philippines100•
Novo Nordisk Pharma (Singapore) Pte Ltd., Singapore100•
Novo Nordisk India Holding Pte Ltd., Singapore100•
Novo Nordisk Pharma Korea Ltd., South Korea100•
Novo Nordisk Lanka (PVT) Ltd, Sri Lanka100•
Novo Nordisk Pharma (Thailand) Ltd., Thailand100•
Novo Nordisk Vietnam Ltd., Vietnam100•
Other subsidiaries and associated companies
Company and countryPercentage of shares ownedActivity
NNE A/S, Denmark100•
NNIT A/S, Denmark18 •
CS Solar Fund XIV, LLC, US99 •


Companies without significant activities are not included in the list.
NNE A/S subsidiaries are not included in the list.